137 results about "Flavolipin" patented technology

The invention discloses a preparation method of second-generation denitrified flavin TND1128, which comprises the following steps: S1, by taking 1-methylbarbituric acid and o-aminobenzaldehyde as raw materials and a mixture of water and alcohol as a solvent, heating and reacting to generate an intermediate I; s2, taking the intermediate I as a raw material, and performing ethylation under the combined action of inorganic alkali and an ethylation reagent to generate a TND1128 crude product; s3, the TND1128 crude product is purified, and a TND1128 pure product is obtained; according to the invention, 1-methylbarbituric acid and 2-nitrobenzaldehyde are taken as raw materials for cyclization synthesis of an intermediate I, then ethylation and pulping purification are carried out under the combined action of inorganic base and an ethylation reagent, and high-purity TND1128 is synthesized in a high-yield, high-specificity and high-selectivity manner; the method has the advantages of simple process route, good reaction selectivity, high yield, cheap and easily available raw materials, low equipment requirement, easy realization of industrial production and the like.

The invention relates to a high-water-solubility denitroflavin covalent complex as well as a preparation method and application thereof, and belongs to the technical field of organic synthesis and medicinal chemistry. Comprising the following steps: (1) firstly, carrying out bromination reaction on 3-methyl-10-ethyl denitroflavin, so as to obtain 3-methyl-10-(1-bromoethyl) denitroflavin; and (2) coupling the 3-methyl-10-(1-bromoethyl) denitroflavin with vitamin C, so as to obtain the high-water-solubility denitroflavin covalent complex. According to the present invention, the prepared highly water-soluble denitrificin covalent complex has the two-phase solubility of the organic solvent and the water, such that the water solubility of the 3-methyl-10-ethyl-denitrificin is substantially enhanced, and the application range of the denitrificin is expanded. And meanwhile, the denitrified flavin covalent compound also has good antioxidant activity, and the antioxidant duration can be prolonged.

The invention relates to an apolipoprotein E detection reagent and application thereof, and belongs to the technical field of biomedicine. The invention provides application of a plant derivative in preparation of an APOE epitope exposure agent. The plant derivative is selected from at least one of curcumin, emodin, EF24 and FLLL-32. The invention also provides an APOE epitope exposure agent which comprises a surfactant, salts, a reducing agent and plant derivatives. According to the present invention, the sample and the protein are pre-treated by using the epitope exposure agent containing the plant derivative to improve the sufficiency of the ApoE protein epitope exposure so as to achieve the accurate typing of the ApoE gene based on the immunological detection method and the accurate quantification of the proteins with different genotypes. Genetic typing of ApoE and quantitative detection of proteins with different genotypes are carried out based on an immunological detection method, and the genotype detection result is highly consistent with a fluorescent PCR (Polymerase Chain Reaction) result.

The invention belongs to the technical field of medicines, and particularly provides a novel application of a theaflavin compound in preparation of a product for inhibiting dipeptidyl peptidase-4 (DPP-4), and the theaflavin compound is one or more of theaflavin-3-gallate (TF2A), theaflavin-3 '-digallate (TF3) and theaflavin (TF). The research systematically proves that TF2A, TF3 and TF have new application of inhibiting DPP-4 for the first time: in-vitro enzymology and fluorescence experiments show that theaflavin can inhibit DPP-4 and interact with DPP-4, and molecular docking further shows possible binding configuration and key action sites of theaflavin. In vivo, the activity of DPP-4 in serum and different tissues of high-fat diet mice can be reduced, serum glucagon-like peptide-1 (GLP-1) can be up-regulated, and glycometabolism and inflammatory phenotype can be improved. Therefore, the theaflavin compound disclosed by the invention can be applied to preparation of products for inhibiting DPP-4, and has a good development prospect.

The invention discloses a method for directionally preparing indigo blue or indirubin by biocatalytically converting indoleglycoside fermentation liquor, which is characterized in that beta-glucosidase Asbg1 and flavin-dependent monooxygenase MaFMO are combined, and the indoleglycoside fermentation liquor is used as a substrate to directionally prepare the indigo blue or indirubin. A glucose dehydrogenase (GDH)-mediated NADPH circulating system is introduced as a process supply cofactor, and then process conditions are optimized and regulated, so that a process for directionally preparing the indigo blue or indirubin by taking the indole glycoside fermentation liquor as a substrate is established, and the directional preparation of the indigo blue or indirubin is realized. The process provides a method for realizing green and efficient directional preparation of indigo blue or indirubin.

The invention discloses application of traditional Chinese medicine monomer poplar bud flavin (including homologues thereof and extracts / mixtures containing the same) in preparation of drugs for treating nerve injury diseases and a preparation method of the drugs for treating the nerve injury diseases. The pharmacological action mechanism of the monomer poplar bud flavin is deeply explored, and animal model application effect verification proves that the monomer poplar bud flavin (including homologues thereof and extracts / mixtures containing the homologues) can obviously improve core symptoms of cerebral apoplexy, autism, Alzheimer's disease and depression models, is high in safety, and can be used for preparing a medicine for treating cerebral apoplexy, autism, Alzheimer's disease and depression models. The invention also develops a medicine for treating cerebral apoplexy, autism, Alzheimer's disease and depression, which takes the poplatin as a core component (including homologues of the poplatin and extracts / mixtures containing the poplatin), and is expected to provide new research results and application schemes for treatment of nerve injury diseases such as cerebral apoplexy, autism, Alzheimer's disease, depression and the like. The important significance is realized on improving the treatment effect.

The application discloses a three-channel fluorescence sensor array based on sulfur quantum dots and a preparation method and detection application thereof. The sensor array is composed of three kinds of sulfur quantum dots, namely C-SQDs, PSS-SQDs and beta-SQDs. When target objects exist, the three kinds of sensing units generate differentiated fluorescence responses, forming a unique "fingerprint map". By using principal component analysis to analyze the response mode, the array can successfully distinguish between structurally similar baicalein, fiscetin, myricetin, quercetin and rutin in a concentration range of 8.0-56 muM. In addition, the array can also perform semi-quantitative analysis on a single flavone compound in a range of 4.0-56 muM, and the first principal component has a good linear relationship with the logarithm of the concentration of the target object.

The invention discloses application of ginkgetin in treatment of chronic pulmonary obstruction, and relates to the field of medical technical methods of ginkgetin. According to the invention, by constructing a model of cigarette extract on airway epithelial cell injury, the biflavone compound is found to have a protective effect on epithelial cell injury caused by smoking; through transcriptomics research, biflavone compounds such as ginkgetin and the like are found to have pharmacological activity of inhibiting CEBP beta protein high expression caused by cigarette extracts, so that the effect of protecting airway inflammation caused by smoking is achieved. More importantly, the ginkgetin and the glucocorticoid are jointly used, so that the treatment effect on chronic pulmonary obstruction is remarkably improved compared with that of independently using the ginkgetin and the glucocorticoid, and the ginkgetin and the glucocorticoid have wide medical application.

The application discloses an evaluation method for distinguishing different quality of momordica grosvenori of different origins. The application adopts high performance liquid chromatography to establish the fingerprint of momordica grosvenori, carries out gradient elution by taking water-acetonitrile as a mobile phase, and detects the wavelength of 203 nm to obtain the HPLC fingerprint of momordica grosvenori; the obtained chromatogram is introduced into a traditional Chinese medicine chromatographic fingerprint similarity evaluation system to generate a control fingerprint, different origins of momordica grosvenori are distinguished through similarity comparison and / or chemical pattern recognition analysis; and chemical markers with VIP>1 such as 5-hydroxymethyl furfural, momordica grosvenori flavonoid, momordica grosvenori saponin V and momordica grosvenori saponin IIIA2 are screened. The application can effectively distinguish two main origins of green skin fruit and red hair fruit, overcomes the defects that traditional trait identification is subjective and it is difficult to distinguish similar appearance samples, and provides an objective, accurate and stable technical means for origin identification, quality consistency evaluation and authenticity identification of momordica grosvenori.

The invention provides a broad-spectrum combined medicine for treating colorectal cancer. The broad-spectrum combined medicine is prepared from the following components in parts by weight: 100 parts of purified water, 38 to 90 parts of tripterygium wilfordii alkaloid, 38 to 90 parts of tripterygium hypoglaucum alkaloid, 28 to 85 parts of chamaejasmine, 28 to 85 parts of gelsmium elegans alkaloid and 28 to 85 parts of xanthoxylin. The medicine is prepared from the following raw materials in parts by weight: 16 to 80 parts of ganoderan, 16 to 80 parts of pinellia ternate sitosterol, 16 to 80 parts of radix rehmanniae praeparata, 16 to 80 parts of astragaloside, 16 to 80 parts of oldenlandia diffusa alkaloid, 16 to 80 parts of sculellaria barbata alkaloid, 16 to 80 parts of tanshinone, 16 to 80 parts of carthamin, 16 to 80 parts of honeysuckle chlorogenic acid and 16 to 80 parts of pericarpium citri reticulatae flavone. By integrating anti-tumor components with multiple action mechanisms, tripterygium wilfordii alkaloid, tripterygium hypoglaucum alkaloid and the like, tumor cell proliferation can be directly inhibited, and apoptosis can be induced; tanshinone, emodin and the like can inhibit tumor angiogenesis; ganoderma lucidum polysaccharides, astragaloside and the like can activate the immune system of the body, enhance the activity of T cells and NK cells, and form double strikes of direct killing and immune surveillance.

Methods for producing organosulfur compounds from a prokaryotic cell comprising enzymes involved in the production of cysteamine, hypotaurine, and taurine. Said prokaryote may comprise a vanin selected from vanin-1 (vnn-1), vanin-2 (vnn-2), or vanin- 3 (vnn-3), a cysteamine dioxygenase (ado), and / or a flavin-containing monooxygenase 1 (fmo1). Methods include the expression of organosulfur compounds in Corynebacterium glutamicum with incubation conditions to promote compound production.

This invention relates to the field of biomedicine, and discloses the application of flavin-containing monooxygenase 2 in the preparation of drugs for the treatment of non-alcoholic fatty liver disease. This invention is the first to discover that flavin-containing monooxygenase 2 has a preventive or therapeutic effect on non-alcoholic fatty liver disease.

This invention provides an improved method for electrochemical glucose measurement and an improved composition for glucose measurement. This invention also provides a composition for glucose measurement comprising a flavin compound. This invention also provides an electrode comprising a flavin compound and a sensor and a glucose fuel cell comprising such electrode. In addition, this invention provides a method for electrochemical glucose measurement and a method for electric power generation using a flavin compound. The flavin compound of the present invention is non-toxic or less toxic and it can be thus used for a means of self-contained continuous glucose measurement.

The present invention relates to a method for producing a product using an enzyme comprising a prenylated flavin mononucleotide (prFMN) cofactor in a recombinant microorganism, wherein the recombinant microorganism is grown in a culture medium in the absence of air, and wherein the recombinant microorganism recombinantly expresses a polypeptide that facilitates the oxidative maturation of a prFMNH2 precursor into the active prFMN cofactor. Further provided are recombinant microorganism for use in such methods.

The present invention relates to a treatment of cancer. Here, the inventors discovered that flavin-containing monooxygenase 4 (FM04) expression was increased in lung tumor samples compared with lung healthy tissue. They found that this phenotype was a common feature in lung adenocarcinoma promoted also by translocation of EML4 / ALK as well as by oncogenic KRAS or EGFR using dedicated mouse models. Moreover, FMO4 was strongly increased in human lung tumors compared with healthy lung tissue, and FMO4 expression was inversely correlated with overall survival in patients with lung adenocarcinoma. Importantly, FMO4 protected lung cancer cells against reactive oxidative species-induced apoptosis. Finally, FMO4 loss of function decreased oncogenic KRAS-induced human bronchoalveolar cells transformation in vitro and in vivo. Thus, the present invention relates to an FMO inhibitor for use in the treatment of cancer in a subject in need thereof.

According to the folium artemisiae argyi extract, the preparation method thereof and the application of the folium artemisiae argyi extract in growth promotion, the folium artemisiae argyi extract required by a plant biostimulant comes from folium artemisiae argyi, the folium artemisiae argyi extract has the advantages of being rich in source, easy to extract and the like, green and sustainable agricultural development is facilitated, and a new scheme is provided for yield increase of crops. According to the extract, leaves and stems of traditional Chinese medicine folium artemisiae argyi serve as raw materials and are subjected to two times of ultrasonic extraction (absolute ethyl alcohol), filtrate is combined, then a crude extract is prepared, a purified component is a 60% ethanol component obtained by separating the crude extract through macroporous resin, the purified component mainly comprises a flavonoid component, and the content of eupatilin is the highest. The plant height, leaf length and fresh weight of rice, pakchoi, cotton and soybean are all improved after the fertilizer is applied according to the application mode mentioned in the invention.

The invention relates to a method for preparing irisflorentin by utilizing belamcandin, and belongs to the technical field of biology. The method comprises the following steps: carrying out C-5 site and C-3'site methylation reaction by taking white belamcandin as a substrate, taking belamcanda methyl transferase gene BcOMT03 gene encoding protein and belamcanda methyl transferase BcOMT33 gene encoding protein as catalysts and taking S-adenosine-methionine as a methyl donor to generate a corresponding glycosylation product. According to the invention, the functions of the two methyltransferase genes BcOMT03 and BcOMT33 in the blackberry lily are identified and verified for the first time, the effect of the two methyltransferase genes BcOMT03 and BcOMT33 in catalyzing the ibullamcandin to produce the irisflorentin is defined, and the blank of research on the biosynthetic pathway of the characteristic component irisflorentin of the blackberry lily is filled up; important information is provided for research on a biosynthesis mechanism of active ingredients of medicinal plants.

Provided herein are compositions and methods for measuring the levels of flavins (e.g., in biological samples). In particular, provided herein are modified biotin-riboflavin conjugates and uses thereof (e.g., to measure flavin levels).

A genetically modified prokaryotic cell to express enzymes involved in the production of taurine. Said prokaryote comprises a vanin selected from: vanin- 1 (vnn-1), vanin-2 (vnn-2), or vanin- 3 (vnn-3), a cysteamine dioxygenase (ado), and a flavin-containing monooxygenase 1 (fmol), in addition to either the addition, alteration, or deletion of at least one gene involved in taurine synthesis or transport.

The invention belongs to the technical field of Chinese wolfberry processing, and particularly relates to fresh Chinese wolfberry primary pulp rich in high-value active ingredients and a production method of the fresh Chinese wolfberry primary pulp. The method is characterized in that grinding-pulsed electric field circulation treatment is carried out, so that the retention rate of heat-sensitive active ingredients such as lycium barbarum polysaccharide, carotenoid and vitamins is increased, the flavone content is 0.41-0.45 g / 100 g, the lycium barbarum polysaccharide content is 0.54-0.57 g / 100 g, the beta-carotene content is 0.55-0.60 mg / g, the zeaxanthine content is 1.28-1.35 mg / g, the betaine content is 0.340-0.366 g / 100 g, and the linoleic acid content is 0.052-0.057 g / 100 g. The content of all nutrient elements in the Chinese wolfberry primary pulp in the prior art is far higher, and the nutrition and the efficacy value of the fresh Chinese wolfberry fruits are maximized.

The invention provides application of a flavin monooxygenase 3 inhibitor in preparation of a medicine for preventing and / or treating acute pancreatitis, and belongs to the technical field of medicines. The flavin monooxygenase 3 inhibitor is methimazole or a pharmaceutically acceptable salt, a prodrug or a derivative of methimazole. Experimental results show that after the methimazole is orally taken, the nidus area of animal pancreatitis is obviously reduced, the pathological score is obviously improved, the in-vivo inflammation level is obviously inhibited, and the blood amylase and lipase levels are obviously reduced; the levels of pancreatitis factors and chemotactic factors are reduced, and the oxidative stress index is reduced. In addition, by combining methimazole with the traditional Chinese medicine monomer for inhibiting the trimethylamine oxide level, the curative effect is better. Compared with the prior art, the application has the advantages that the core regulation effect of the trimethylamine oxide in the pathological process of the acute pancreatitis is disclosed for the first time, the limitation of the traditional anti-inflammatory or enzyme replacement therapy is broken through, and the acute pancreatitis is treated by inhibiting the trimethylamine oxide level by inhibiting the flavin monooxygenase 3.

Provided is a composition comprising 20-40 parts by weight of cordyceps militaris powder, 3-25 parts by weight of theaflavins, and 1.25-4.2 parts by weight of astaxanthin, which is a whitening composition or a melanin synthesis signal antagonizing composition. The composition can be used as a main ingredient in whitening food or health food.

The invention relates to the technical field of traditional Chinese medicines, and discloses a classic prescription for treating hypoovarian reserve function, which is prepared from the following raw materials: 30 to 40g of Chinese yam, 20 to 30g of semen cuscutae, 10 to 20g of fructus lycii, 10 to 15g of radix achyranthis bidentatae, 10 to 20g of codonopsis pilosula, 10 to 20g of poria cocos, 20 to 30g of malt, 10 to 15g of angelica sinensis and 10 to 30g of radix puerariae. The classical prescription for treating the hypoovarian reserve function has a positive curative effect, and modern network pharmacology also scientifically proves that active ingredients such as quercetin, daidzein, kaempferol and the like contained in the kidney-tonifying and menstruation-regulating prescription are flavonoid compounds from the aspect of action mechanism, so that the prescription has very good anti-inflammatory and anti-oxidative stress ovarian protection effects; the application range is wide, clinical manifestations of patients with the ovarian reserve function decline are generally hypomenorrhea, menoxenia, amenorrhea, infertility or perimenopausal symptoms, and the kidney tonifying and menstruation regulating prescription has a certain regulating effect on the hypomenorrhea.

This invention discloses a bifunctional flavin adenine dinucleotide synthase mutant and its application in FAD synthesis. The mutant disclosed in this invention is RFK / FADS. C18R or RFK / FADS C18R‑R46H ;RFK / FADS C18R The amino acid sequence is shown in SEQ ID NO.15, RFK / FADS C18R‑R46H The amino acid sequence is shown in SEQ ID NO. 16. Genetically engineered bacteria carrying the bifunctional flavin adenine dinucleotide synthase mutant gene plasmid produced flavin adenine dinucleotide using glucose as a substrate through a simple fermentation process under aerobic conditions in a shake flask. The FAD yields of strains XF02 and XF03 containing the mutant gene were 79.31 mg / L and 167.56 mg / L, respectively, representing increases of 58.62% and 235.12% compared to strain XF01 containing the non-mutated gene. By constructing microbial "cell factories" through metabolic engineering strategies, modified microorganisms can utilize inexpensive raw materials to generate desired natural products within their cells. This advancement not only reduces the production cost of FAD but also improves the environmental sustainability of its production process.

The invention discloses a pharmaceutical composition for resisting non-small cell lung cancer as well as a preparation method and application of the pharmaceutical composition, belongs to the technical field of antitumor drugs, and mainly solves the technical problem that application is affected due to the fact that an Iridobelamal A compound has high toxicity to normal lung cells. The composition provided by the invention comprises the following active components: an iridoaldehyde triterpenoid compound Iridobelamal A and a flavonoid compound tectorigenin, the molar ratio of the Iridobelamal A to the tectorigenin is 1: 2-1: 5, the molecular formula of the Iridobelamal A is C30H50O4, the molecular formula of the tectorigenin is C16H12O6, and the composition and a pharmaceutical carrier are prepared into an oral preparation or an injection. The composition is used for preparing a medicine for treating non-small cell lung cancer by neutralizing triterpene toxicity and synergistically enhancing anti-tumor activity.

The invention discloses a preparation method of high-activity theaflavin. The method sequentially comprises the following steps: preparation and enzyme purification of tea powder, ultrasonic-assisted enzymolysis, oil-water double-liquid phase step type fermentation and online extraction, chromatographic column separation and purification, and membrane concentration and drying. According to the method, an oil-water double-liquid-phase enzymatic oxidation system is constructed, the fermentation process and the extraction process are coupled, the characteristic that the target product theaflavin-3, 3 '-digallate has a higher partition coefficient in an organic phase is utilized, in-situ separation and enrichment in the reaction process are achieved, and product degradation is avoided. In combination with a subsequently adopted specific chromatographic separation technology, the content of the high-activity TF3 monomer in the product is finally successfully increased to 50% or above of the total theaflavin monomer, and the biological activity of the product is improved.

The invention provides application of delphinidin-3-glucoside in preparation of uric acid reducing drugs or functional products, and belongs to the technical field of medical application. According to the invention, a novel component-target-metabolic pathway (C-T-M) network is constructed, and the network provides a comprehensive method for analyzing a specific component target and the effect of the specific component target in influencing the metabolic pathway of the HUA. Molecular dynamics (MD) simulation and surface plasmon resonance (SPR) technologies are adopted, and in-vitro and in-vivo metabonomics researches are carried out. The invention discloses a uric acid reducing effect of Dp-3G in red kidney beans, and the uric acid reducing effect is realized by combining with a flavin adenine dinucleotide (FAD) site of xanthine oxidase (XO) enzyme. Therefore, the research provides a new insight for preventing and treating the HUA by specific beans and key natural medicines.

The invention discloses an agricultural composition for preventing and treating powdery mildew of cucumbers, and belongs to the technical field of pesticides. The effective components of the agricultural composition provided by the invention consist of the physcion and the beta-lupin globulin polypeptide, and the mass ratio of the physcion to the beta-lupin globulin polypeptide is (4: 1)-(1: 8). The two components are compounded for use within the ratio range to achieve a synergistic effect.

This invention provides an immune-enhancing theaflavin composition, its preparation method, and its application, belonging to the field of biotechnology. The composition comprises *Schlumbergera truncata* extract peptides, theaflavins, and *Spatholobus suberectus* kernel extract. The *Schlumbergera truncata* extract peptides contain peptides between 1000 Da and 3000 Da obtained through trypsin hydrolysis of *Schlumbergera truncata*. This invention employs a special method to obtain *Schlumbergera truncata* extract peptides and *Spatholobus suberectus* kernel extract, and designs a more efficient compounding ratio of *Schlumbergera truncata* extract peptides, theaflavins, and *Spatholobus suberectus* kernel extract. The combined use of these three components exhibits excellent immune-enhancing effects, significantly improving the efficacy compared to using theaflavins alone and effectively enhancing the utilization of theaflavins.

The invention discloses the phenazine halogenase PezW for the first time; the halogenase PezW is derived from streptomyces tubercidicus NBRC 13090, and belongs to a flavin dependent type halogenase, and the flavin dependent type halogenase PezW is a flavin dependent type halogenase. The invention also constructs an expression vector containing a nucleotide sequence for coding the phenazine halogenase PezW, a cloning expression method of the phenazine halogenase PezW, and an application of the phenazine halogenase PezW in preparation of halogenated modified compounds. Wherein the compound is hydroxylated phenazine. The halogenation modification is as follows: halogen atoms of a halogen donor are transferred and combined to a phenazine compound; and the halogen donor is NaCl, NaBr or NaI. According to the halogenase PezW, hydroxylated phenazine can be used as a substrate, various halogenated hydroxyphenazine can be obtained, the technical blank of preparing hydroxylated phenazine by an enzyme method is filled, and a remarkable technical effect is achieved. The method not only has milestone significance for the technical development of enzymatic synthesis of HHPs, but also provides a new path for the drug development of phenazine compounds, and has important application value and social significance.